BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

66 related articles for article (PubMed ID: 1650226)

  • 1. Single- and multiple dose pharmacokinetics of lonidamine in patients suffering from non-small-cell lung cancer.
    Gatzemeier U; Toomes H; Picollo R; Christoffel V; Lücker PW; Ulmer J
    Arzneimittelforschung; 1991 Apr; 41(4):436-9. PubMed ID: 1650226
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacokinetics of low-dose nedaplatin and validation of AUC prediction in patients with non-small-cell lung carcinoma.
    Niioka T; Uno T; Yasui-Furukori N; Takahata T; Shimizu M; Sugawara K; Tateishi T
    Cancer Chemother Pharmacol; 2007 Apr; 59(5):575-80. PubMed ID: 16912889
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical pharmacology of gallium chloride after oral administration in lung cancer patients.
    Collery P; Millart H; Lamiable D; Vistelle R; Rinjard P; Tran G; Gourdier B; Cossart C; Bouana JC; Pechery C
    Anticancer Res; 1989; 9(2):353-6. PubMed ID: 2546482
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A safety and pharmacokinetic study of a mixed-backbone oligonucleotide (GEM231) targeting the type I protein kinase A by two-hour infusions in patients with refractory solid tumors.
    Chen HX; Marshall JL; Ness E; Martin RR; Dvorchik B; Rizvi N; Marquis J; McKinlay M; Dahut W; Hawkins MJ
    Clin Cancer Res; 2000 Apr; 6(4):1259-66. PubMed ID: 10778949
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy and safety of axitinib in patients with advanced non-small-cell lung cancer: results from a phase II study.
    Schiller JH; Larson T; Ou SH; Limentani S; Sandler A; Vokes E; Kim S; Liau K; Bycott P; Olszanski AJ; von Pawel J
    J Clin Oncol; 2009 Aug; 27(23):3836-41. PubMed ID: 19597027
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The pharmacokinetics of oral lonidamine in breast and lung cancer patients.
    Newell DR; Mansi J; Hardy J; Button D; Jenns K; Smith IE; Picollo R; Catanese B
    Semin Oncol; 1991 Apr; 18(2 Suppl 4):11-7. PubMed ID: 2031191
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacokinetic and preliminary metabolic fate of navelbine in humans as determined by high performance liquid chromatography.
    Jehl F; Quoix E; Leveque D; Pauli G; Breillout F; Krikorian A; Monteil H
    Cancer Res; 1991 Apr; 51(8):2073-6. PubMed ID: 1849042
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical pharmacology of chronic oral etoposide in patients with small cell and non-small cell lung cancer.
    Zucchetti M; Pagani O; Torri V; Sessa C; D'Incalci M; De Fusco M; de Jong J; Gentili D; Martinelli G; Tinazzi A
    Clin Cancer Res; 1995 Dec; 1(12):1517-24. PubMed ID: 9815952
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A pharmacokinetic and dose escalation study of pegfilgrastim (KRN125) in lung cancer patients with chemotherapy-induced neutropenia.
    Yamamoto N; Sekine I; Nakagawa K; Takada M; Fukuoka M; Tanigawara Y; Saijo N
    Jpn J Clin Oncol; 2009 Jul; 39(7):425-30. PubMed ID: 19395467
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Phase II study of oral topotecan in advanced non-small cell lung cancer.
    White SC; Cheeseman S; Thatcher N; Anderson H; Carrington B; Hearn S; Ross G; Ranson M
    Clin Cancer Res; 2000 Mar; 6(3):868-73. PubMed ID: 10741709
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Population pharmacokinetics of the photodynamic therapy agent 2-[1-hexyloxyethyl]-2-devinyl pyropheophorbide-a in cancer patients.
    Bellnier DA; Greco WR; Loewen GM; Nava H; Oseroff AR; Pandey RK; Tsuchida T; Dougherty TJ
    Cancer Res; 2003 Apr; 63(8):1806-13. PubMed ID: 12702566
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Phase I study of a five-day dose schedule of 4-Ipomeanol in patients with non-small cell lung cancer.
    Kasturi VK; Dearing MP; Piscitelli SC; Russell EK; Sladek GG; O'Neil K; Turner GA; Morton TL; Christian MC; Johnson BE; Kelley MJ
    Clin Cancer Res; 1998 Sep; 4(9):2095-102. PubMed ID: 9748125
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacokinetics of a novel anticancer ruthenium complex (KP1019, FFC14A) in a phase I dose-escalation study.
    Lentz F; Drescher A; Lindauer A; Henke M; Hilger RA; Hartinger CG; Scheulen ME; Dittrich C; Keppler BK; Jaehde U;
    Anticancer Drugs; 2009 Feb; 20(2):97-103. PubMed ID: 19209025
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Phase II study of lonidamine in patients with small cell carcinoma of the lung.
    Murray N; Shah A; Band P
    Cancer Treat Rep; 1987 Dec; 71(12):1283-4. PubMed ID: 2825992
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Phase I study of N(1),N(11)-diethylnorspermine in patients with non-small cell lung cancer.
    Hahm HA; Ettinger DS; Bowling K; Hoker B; Chen TL; Zabelina Y; Casero RA
    Clin Cancer Res; 2002 Mar; 8(3):684-90. PubMed ID: 11895896
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Phase I study of TZT-1027, a novel synthetic dolastatin 10 derivative, for the treatment of patients with non-small cell lung cancer.
    Horti J; Juhasz E; Monostori Z; Maeda K; Eckhardt S; Bodrogi I
    Cancer Chemother Pharmacol; 2008 Jun; 62(1):173-80. PubMed ID: 18214483
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Investigating the relationship between serum thrombopoietin kinetics and the platelet-sparing effect: A clinical pharmacological evaluation of combined paclitaxel and carboplatin in patients with non-small cell lung cancer.
    Daga H; Isobe T; Miyazaki M; Fujitaka K; Kondo K; Kohno N
    Oncol Rep; 2004 Jun; 11(6):1225-31. PubMed ID: 15138560
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Lonidamine: efficacy and safety in clinical trials for the treatment of solid tumors.
    Di Cosimo S; Ferretti G; Papaldo P; Carlini P; Fabi A; Cognetti F
    Drugs Today (Barc); 2003 Mar; 39(3):157-74. PubMed ID: 12730701
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A phase I and pharmacologic evaluation of the DNA intercalator CI-958 in patients with advanced solid tumors.
    Dees EC; Whitfield LR; Grove WR; Rummel S; Grochow LB; Donehower RC
    Clin Cancer Res; 2000 Oct; 6(10):3885-94. PubMed ID: 11051234
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Pilot phase II study of 5-day continuous infusion of cisplatin in treatment of non-small cell lung cancer].
    Saito Y; Mori K; Yokoi K; Tominaga K; Miyazawa N
    Gan To Kagaku Ryoho; 1989 May; 16(5):2081-6. PubMed ID: 2543330
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.